- Home
- AFRI vs RVNC Comparison
AFRI vs RVNC Comparison
Compare AFRI & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRI
- RVNC
- Stock Information
- Founded
- AFRI 1943
- RVNC 1999
- Country
- AFRI Gibraltar
- RVNC United States
- Employees
- AFRI N/A
- RVNC N/A
- Industry
- AFRI Packaged Foods
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- AFRI Consumer Staples
- RVNC Health Care
- Exchange
- AFRI Nasdaq
- RVNC Nasdaq
- Market Cap
- AFRI 275.5M
- RVNC 320.5M
- IPO Year
- AFRI N/A
- RVNC 2014
- Fundamental
- Price
- AFRI $10.06
- RVNC $3.47
- Analyst Decision
- AFRI
- RVNC Hold
- Analyst Count
- AFRI 0
- RVNC 9
- Target Price
- AFRI N/A
- RVNC $7.78
- AVG Volume (30 Days)
- AFRI 10.7K
- RVNC 3.7M
- Earning Date
- AFRI 01-14-2025
- RVNC 02-26-2025
- Dividend Yield
- AFRI N/A
- RVNC N/A
- EPS Growth
- AFRI N/A
- RVNC N/A
- EPS
- AFRI N/A
- RVNC N/A
- Revenue
- AFRI $305,476,000.00
- RVNC $256,945,000.00
- Revenue This Year
- AFRI N/A
- RVNC $11.28
- Revenue Next Year
- AFRI N/A
- RVNC $27.21
- P/E Ratio
- AFRI N/A
- RVNC N/A
- Revenue Growth
- AFRI 5.42
- RVNC 25.82
- 52 Week Low
- AFRI $9.63
- RVNC $2.30
- 52 Week High
- AFRI $12.00
- RVNC $7.59
- Technical
- Relative Strength Index (RSI)
- AFRI 45.28
- RVNC 53.03
- Support Level
- AFRI $10.01
- RVNC $3.06
- Resistance Level
- AFRI $10.36
- RVNC $3.09
- Average True Range (ATR)
- AFRI 0.28
- RVNC 0.03
- MACD
- AFRI -0.00
- RVNC 0.08
- Stochastic Oscillator
- AFRI 27.37
- RVNC 75.86
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.